- Home
- OCS
as 11-07-2025 3:52pm EST
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
| Founded: | 2003 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.0B | IPO Year: | N/A |
| Target Price: | $41.00 | AVG Volume (30 days): | 99.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.00 - $23.08 | Next Earning Date: | 11-06-2025 |
| Revenue: | $960,668 | Revenue Growth: | -12.29% |
| Revenue Growth (this year): | 32.89% | Revenue Growth (next year): | 1043.16% |
Latest Oculis Holding AG Ordinary shares News
OCS Breaking Stock News: Dive into OCS Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
GlobeNewswire
25 days ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
GlobeNewswire
25 days ago
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
Zacks
a month ago
Oculis Holding AG (OCS) Soars 6.3%: Is Further Upside Left in the Stock?
Simply Wall St.
a month ago
Oculis Holding (NasdaqGM:OCS) Valuation Spotlight as Privosegtor Advances Toward Pivotal Neuroprotection Trials
GlobeNewswire
a month ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
MT Newswires
a month ago
Oculis to Advance Privosegtor to Registrational Trials for Neuro-Ophthalmology Indications
GlobeNewswire
a month ago
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
Compare OCS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCS Oculis Holding AG Ordinary shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.